Floatz logo

Diammonium Glycyrrhizinate

Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy

Tongji HospitalSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

270 Active assets in the Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Diammonium Glycyrrhizinate is also rated in:

chronic hepatitis B virus infectionDormant
BB
Indicative ·
65 / 100
View asset →
hepatitisDormant
BB
Indicative ·
65 / 100
View asset →
hepatocellular carcinomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →